Exelixis | EXEL - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
Agios Pharmaceuticals USD 1.03B 83.09M 2026-06
Akebia Therapeutics USD 25.02M 2.36M 2026-06
Amgen USD 11.69B 2.5B 2026-06
AstraZeneca USD 50.3B 2.96B 2026-06
Bayer EUR 29.71B 863M 2026-06
BioMarin Pharmaceutical USD 6.32B 109.58M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cytokinetics USD -173.49M 653.08M 2026-06
Eisai JPY 906.56B 7.57B 2026-06
Eli Lilly USD 33.88B 2.68B 2026-06
Exelixis USD 1.84B 91.99M 2026-06
Genmab DKK 5.96B 275M 2026-06
Glaxosmithkline GBP 17.42B 4.64B 2026-03
Incyte USD 6.34B 721.58M 2026-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 41.93B 3.94B 2026-06
Moderna USD 6.76B 647M 2026-06
Nektar Therapeutics USD 576.22M 486.38M 2026-03
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Novartis USD 41.95B 3.02B 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Puma Biotechnology USD 115.27M 10.55M 2025-09
Sanofi EUR 73.14B 1.43B 2026-03
Takeda JPY 7.56T 215.7B 2026-06
Ultragenyx Pharmaceutical USD -291M 55M 2026-06
Xencor USD 503.23M 12.4M 2026-06